autologous blood and marrow transplantation - Blog Science ...

486 Chapter 9: Long-Term Effects
Table 2. Study 2 patient characteristics
n 12
Age (years)
56 (7-77)
Sex
Males 7
Females
FAB category
RA
RAEB
RAEBt
CMML 3 62 1
De novo/secondary
De novo
Secondary
Posttransplant
CMML, chronic myelomonocytic leukemia; RA, refractory anemia; RAEB, refractory ane­
mia with excess blasts; RAEBt, refractory anemia with excess blasts in transformation.
pretransplant specimens. One patient's specimen was analyzed using FISH probes
for two different karyotypic abnormalities, with similar results for each.
In three cases, the number of abnormal cells identified in the pretransplant
specimen fell below our conservative 10% threshold, indicating that the clonal
karyotypic abnormality may not have been present in these cases before
HDC/autologous transplantation. This group included the only patient who had
received no antineoplastic therapy before HDC/autologous transplantation.
Study 2: Analysis of immunomagnetically sorted CD34-positive progenitors
Data from the 12 évaluable patients are summarized in Fig. 2. In seven of 12
cases (group 1), the patient's clonal marker segregated preferentially with the
CD34-negative cell fraction, suggesting at least partial sparing of the CD34positive
fraction. In the other five cases (group 2), there was no difference in the
proportions of abnormal cells in the CD34-negative and CD34-positive fractions.
Among the 12 specimens were pretransplant specimens from two patients with
posttransplant MDS also included in study 1 above; one fell into each group with
respect to CD34 selection results.
There were no obvious differences between the two groups of patients, although
those whose marker segregated with the CD34-negative fraction had somewhat
less advanced and/or lower risk MDS when compared with the group whose
markers did not segregate with CD34 expression.
5
7
5
2